The toll-like receptor 2 agonist Pam3CSK4 is neuroprotective after spinal cord injury

Nicole S Stivers1, Nicolas Pelisch1, Ben C Orem1

  • 1Kentucky Spinal Cord Injury Research Center and Departments of Neurological Surgery, Microbiology and Immunology, Anatomical Sciences and Neurobiology, University of Louisville, Louisville, KY, USA.

Experimental Neurology
|April 27, 2017
PubMed

Insights

Stimulating Toll-like receptor-2 (TLR2) with Pam3CSK4 enhances microglial response after spinal cord injury (SCI), reducing axonal damage and improving oligodendroglia survival for neuroprotection.

Area of Science:

  • Neuroscience
  • Immunology
  • Regenerative Medicine

Background:

  • Microglia/macrophage activation after spinal cord injury (SCI) has dual roles, impacting both damage and repair.
  • Toll-like receptor-2 (TLR2) stimulation shows promise for SCI recovery and axonal regeneration, but mechanisms are unclear.
  • Microglia are key players in the inflammatory response to SCI, expressing high levels of TLR2.

Purpose of the Study:

  • To investigate if modulating microglial response via a TLR2 agonist, Pam3CSK4, can prevent secondary white matter degeneration after SCI.
  • To elucidate the mechanisms underlying TLR2 agonist-mediated neuroprotection in the context of SCI.

Main Methods:

  • Utilized an ex vivo laser-induced SCI (LiSCI) model in double transgenic mice (GFP in microglia/oligodendroglia, YFP in axons).
  • Visualized myelin using Nile Red dye and tracked acute changes in microglia, axons, and oligodendroglia using two-photon excitation microscopy.
  • Administered Pam3CSK4 one hour post-injury and performed microarray analysis to assess microglial activation profiles.

Main Results:

  • Pam3CSK4 treatment significantly enhanced the extent and timing of microglial response 2-4 hours post-SCI.
  • Pam3CSK4 significantly reduced axonal dieback and secondary axonal damage at 6 hours post-SCI.
  • Pam3CSK4 treatment improved oligodendroglia survival and induced a mixed M1:M2 microglial activation profile.

Conclusions:

  • Modulating microglial activation through TLR2/TLR1 signaling with Pam3CSK4 is a viable neuroprotective strategy following SCI.
  • Pam3CSK4 treatment in situ mitigates secondary degeneration and promotes neuronal and glial survival after spinal cord injury.
  • Targeting TLR2 offers a promising therapeutic avenue for enhancing recovery after spinal cord injury.

Related Concept Videos